Dr. Kalos Joins IMV’s Board of Directors
IMV Inc. – headquartered in Dartmouth, Nova Scotia – has announced Dr. Michael Kalos will join their Board of Directors. Dr. Kalos is an internationally recognized expert in T cell therapy and immunotherapy and plans to bring his over 25 years of experience to the company. IMV is a clinical-stage biopharmaceutical company focused on the development of novel classes of immunotherapies.
Their key focus is on the development of maveropepimut-S and the company is excited to include Dr. Kalos’ expertise in guiding their development. Maveropepimut-S is their leading drug candidate which aims to generate cancer-targeted T cells in vivo.
“As we broaden our pipeline of immunotherapy candidates, we are thrilled to be able to leverage Michael’s expertise in oncology clinical development. We look forward to his strategic insights in guiding the advancement of our lead immunotherapy toward potential registration and commercialization,” said Fred Ors, Chief Executive Officer at IMV.
Dr. Kalos has served as the Executive Vice President and Head of R&D at ArsenalBio, helping guide them through their development of their first product. Prior, he served as Vice President of Immuno-oncology and Oncology Cell Therapies at Janssen – pharmaceutical company of Johnson and Johnson. His expertise in oncology and R&D of pharmaceuticals will bring great insight into next steps for IMV.
Who We Are:
Swanson Reed is one of Canada’s largest Specialist SR&ED tax advisory firms. We manage all facets of the SR&ED tax credit program, from claim preparation and audit compliance to claim disputes.
If you would like to find out more about how your business could benefit from R&D Tax Credit, contact a Swanson Reed R&D Tax Advisor today.